Pharmacoeconomic Comparison between Chronochemotherapy and Folfox Regimen in the Treatment of Patients with Metastatic Colorectal Cancer: A Cost-Minimization Study
暂无分享,去创建一个
M. Brizzi | L. Dogliotti | M. Tampellini | M. Tucci | R. Bitossi | A. Saini | I. Alabiso
[1] M. Sculpher,et al. Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy , 2000, PharmacoEconomics.
[2] F Levi,et al. Mortality from major cancer sites in the European Union, 1955-1998. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] David C. Dale,et al. Colony-Stimulating Factors for the Management of Neutropenia in Cancer Patients , 2002, Drugs.
[4] A. Hendlisz,et al. Advanced colorectal cancer treatment in Europe: what have we achieved? , 2002, Anti-cancer drugs.
[5] C. la Vecchia,et al. Cancer Mortality in Italy, 1998 , 2002, Tumori.
[6] C. Focan. Pharmaco-economic comparative evaluation of combination chronotherapy vs. standard chemotherapy for colorectal cancer , 2002, Chronobiology international.
[7] C. la Vecchia,et al. Cancer Mortality in Italy, 1997: Quantifying the Fall in Rates in Women and Men , 2001, Tumori.
[8] C. Tournigand,et al. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma , 2001, Cancer.
[9] J. Lotz,et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). , 2001, European journal of cancer.
[10] C. Tournigand,et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] J. Armitage,et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] I. Durand-zaleski,et al. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] F. Lévi,et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] N. Neymark,et al. The costs of managing patients with advanced colorectal cancer in 10 different European centres. , 1999, European journal of cancer.
[16] O. Bouché,et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] F. Lévi,et al. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5‐fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma , 1999, Cancer.
[18] F. Goldwasser,et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F. Lévi,et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] C. Tournigand,et al. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). , 1998, European journal of cancer.
[21] F. Lévi,et al. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer , 1997, The Lancet.
[22] M. Stevens,et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Lokich,et al. Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] F. Lévi,et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] H. Keizer,et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Cunningham,et al. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. , 1996, European journal of cancer.
[27] J. Mayordomo,et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. , 1995, Journal of the National Cancer Institute.
[28] J. Lokich,et al. Infusional cancer chemotherapy: historical evolution and future development at the Cancer Center of Boston. , 1995, Cancer investigation.
[29] F. Lévi,et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. , 1994, Journal of the National Cancer Institute.
[30] A. Reinberg,et al. A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer , 1992, Cancer.
[31] L. Tomatis,et al. Cancer Mortality in Italy , 1990, Tumori.
[32] J. Misset,et al. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). , 1986, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.